Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R T Penson

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
The Oncologist|August 31, 2000
Sexuality and cancer: conversation comfort zoneR T Penson, J Gallagher, M E Gioiella, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2016
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safetyU A Matulonis, R T Penson, S M Domchek, et al.
Gynecologic Oncology|February 16, 2019
Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian originC N Krasner, C Castro, R T Penson, et al.
Gynecologic Oncology|March 27, 2016
A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancerR T Penson, E Sales, L Sullivan, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 10, 2001
Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxelR. T. Penson, K. Kronish, Z. Duan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2022
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancerK E Francis, S I Kim, M Friedlander, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 30, 2022
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trialJ S Frenel, J W Kim, N Aryal, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
The Oncologist|August 31, 2000
Sexuality and cancer: conversation comfort zoneR T Penson, J Gallagher, M E Gioiella, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2016
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safetyU A Matulonis, R T Penson, S M Domchek, et al.
Gynecologic Oncology|February 16, 2019
Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian originC N Krasner, C Castro, R T Penson, et al.
Gynecologic Oncology|March 27, 2016
A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancerR T Penson, E Sales, L Sullivan, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 10, 2001
Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxelR. T. Penson, K. Kronish, Z. Duan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2022
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancerK E Francis, S I Kim, M Friedlander, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 30, 2022
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trialJ S Frenel, J W Kim, N Aryal, et al.
Pageof 5